boplatin plus paclitaxel) treatment from August 2007 to February 2008. Adverse effects (AEs), objective response rate (ORR), median time to progression (TTP), and overall survival (OS) were measured. Results AEs were generally mild and reversible.
The most frequent AEs were alopecia, peripheral neuropathy, rash, proteinuria, nausea/vomitting, fatigue, myalgia, bleeding, and hypertension. The partial remission and stable disease rates were 68% and 28%, respectively. The median TTP and OS of all patients were 11.2 and 19.3 months, respectively. Conclusion Bevacizumab combined with carboplatin-based chemotherapy may be well tolerated and beneficial for Chinese patients with non-squamous NSCLC.
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